LENZ Therapeutics (LENZ) Other Accumulated Expenses (2020 - 2023)

LENZ Therapeutics (LENZ) has 4 years of Other Accumulated Expenses data on file, last reported at $143000.0 in Q4 2023.

• Other Accumulated Expenses for Q4 2023 came in at $143000.0, down 89.44% year-over-year; the trailing twelve-month figure through Dec 2023 was $143000.0 (down 89.44% YoY), and the FY2023 annual result was $143000.0, down 89.44% from the prior year.
• Other Accumulated Expenses declined to $143000.0 in Q4 2023 per LENZ's latest filing, from $221000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $4.9 million in Q1 2023 and troughed at $71000.0 in Q4 2020.
• A 4-year average of $1.0 million and a median of $420500.0 in 2021 frame the typical range for Other Accumulated Expenses.
• On a YoY basis, Other Accumulated Expenses climbed as much as 1611.17% in 2023 and fell as far as 89.44% in 2023.
• A 4-year view of Other Accumulated Expenses shows it stood at $71000.0 in 2020, then soared by 411.27% to $363000.0 in 2021, then jumped by 273.0% to $1.4 million in 2022, then sank by 89.44% to $143000.0 in 2023.
• Business Quant data shows LENZ's Other Accumulated Expenses at $143000.0 in Q4 2023, $221000.0 in Q3 2023, and $3.1 million in Q2 2023.